Cubist Systematic Strategies’s Lineage Cell Therapeutics LCTX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $395K | Buy |
+435,259
| New | +$395K | ﹤0.01% | 1081 |
|
|
2023
Q2 | – | Sell |
-30,155
| Closed | -$45.2K | – | 2675 |
|
|
2023
Q1 | $45.2K | Buy |
30,155
+5,678
| +23% | +$8.52K | ﹤0.01% | 2540 |
|
|
2022
Q4 | $28.6K | Sell |
24,477
-13,634
| -36% | -$16K | ﹤0.01% | 3006 |
|
|
2022
Q3 | $43K | Sell |
38,111
-50,663
| -57% | -$57.2K | ﹤0.01% | 3347 |
|
|
2022
Q2 | $140K | Buy |
+88,774
| New | +$140K | ﹤0.01% | 3310 |
|
|
2021
Q3 | – | Sell |
-47,500
| Closed | -$135K | – | 3068 |
|
|
2021
Q2 | $135K | Sell |
47,500
-96,200
| -67% | -$273K | ﹤0.01% | 2671 |
|
|
2021
Q1 | $338K | Buy |
+143,700
| New | +$338K | ﹤0.01% | 2187 |
|
|
2020
Q4 | – | Sell |
-91,806
| Closed | -$86K | – | 2640 |
|
|
2020
Q3 | $86K | Buy |
+91,806
| New | +$86K | ﹤0.01% | 2306 |
|